Reuters logo
4 个月前
BRIEF-Adamas says presents ADS-5102 pooled Phase 3 data
2017年4月24日 / 下午1点20分 / 4 个月前

BRIEF-Adamas says presents ADS-5102 pooled Phase 3 data

April 24 (Reuters) - Adamas Pharmaceuticals Inc

* Adamas presents ads-5102 pooled phase 3 data confirming statistically significant reduction in levodopa-induced dyskinesia and off time in people with parkinson’s disease

* Adamas pharmaceuticals inc - new drug application for ads-5102 currently under fda review with august 24, 2017, pdufa date

* Adamas pharmaceuticals- ads-5102 had significant reduction in levodopa-induced dyskinesia and showed statistically significant reduction in off time

* Adamas - about twice as many ads-5102 treated patients as placebo patients reported complete resolution of on time with troublesome dyskinesia at 12 weeks Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below